Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rayaldee for Secondary Hyperparathyroidism in CKD
NCT01651000Phase 3Completed
- Sponsor
- OPKO Health
- Start
- Sep 2012
- Primary completion
- Jul 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of calcifediol in secondary hyperparathyroidism (SHPT), sponsored by OPKO Health. Started Sep 2012; status: completed.
02
Drugs
calcifediol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01651000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01651000.